B

BioNote Inc
KRX:377740

Watchlist Manager
BioNote Inc
KRX:377740
Watchlist
Price: 4 600 KRW -2.13% Market Closed
Market Cap: 469.1B KRW
Have any thoughts about
BioNote Inc?
Write Note

BioNote Inc
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

BioNote Inc
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
B
BioNote Inc
KRX:377740
Cash & Cash Equivalents
â‚©147.4B
CAGR 3-Years
6%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Cash & Cash Equivalents
â‚©564.6B
CAGR 3-Years
-11%
CAGR 5-Years
5%
CAGR 10-Years
30%
SK Bioscience Co Ltd
KRX:302440
Cash & Cash Equivalents
â‚©127B
CAGR 3-Years
72%
CAGR 5-Years
95%
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Cash & Cash Equivalents
â‚©182.9B
CAGR 3-Years
61%
CAGR 5-Years
4%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Cash & Cash Equivalents
â‚©78.4B
CAGR 3-Years
51%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Cash & Cash Equivalents
â‚©37.8B
CAGR 3-Years
48%
CAGR 5-Years
45%
CAGR 10-Years
N/A
No Stocks Found

BioNote Inc
Glance View

Market Cap
469.5B KRW
Industry
Biotechnology

BioNote, Inc. develops veterinary diagnostic composition. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2022-12-22. The firm is engaged in the manufacture and sale of rapid diagnostic kits for humans, diagnosis raw materials such as antigens, antibody cell lines, standards, enzymes and others as well as semi-finished products. The firm is also engaged in the manufacture and sale of rapid immunochemical diagnosis, enzyme immune rebound protein, immunochemical fluorescence diagnosis and other products used for animals.

Intrinsic Value
6 138.02 KRW
Undervaluation 25%
Intrinsic Value
Price
B

See Also

What is BioNote Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
147.4B KRW

Based on the financial report for Dec 31, 2023, BioNote Inc's Cash & Cash Equivalents amounts to 147.4B KRW.

What is BioNote Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 3Y
6%

Over the last year, the Cash & Cash Equivalents growth was -78%. The average annual Cash & Cash Equivalents growth rates for BioNote Inc have been 6% over the past three years .

Back to Top